Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

X
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis; Pelvic pain
  • Focus Registrational; Therapeutic Use
  • Acronyms ELARIS EM-II; ELARIS-II; EM-II; Solstice
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 06 Aug 2020 Results (n=1686) of pooled analysis of two studies (ELARIS I and II) assessing health-related quality of life measured by EP-30, published in the Obstetrics and Gynecology.
    • 20 May 2020 Results of post hoc pooled analysis of ELARIS I and II trial quantifying changes in health-related quality of life (HRQOL) among patients with endometriosis who experience a clinically meaningful reduction in dyspareunia presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 12 Nov 2019 Results of post hoc analysis utilized data from two phase III, randomized, double-blind, placebo-controlled clinical studies (EM-I and EM-II) which evaluated the efficacy of elagolix among women with moderate-to-severe endometriosis-related painpublished in the American Journal of Obstetrics and Gynecology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top